期刊文献+

含MYND结构域的锌指蛋白10的原核表达及其多克隆抗体的制备 被引量:1

Prokaryotic expression of Zinc finger MYND domain-containing protein 10 and preparating its polyclonal antibody
下载PDF
导出
摘要 目的表达纯化含MYND结构域的锌指蛋白10(ZMYND10)的重组蛋白并制备其大鼠多克隆抗体。方法全基因合成ZMYND10基因的开放阅读框,构建原核表达载体p ET-28m-ZMYND10。在大肠杆菌中诱导表达HisZMYND10,利用His标签镍柱纯化His-ZMYND10重组蛋白,并用泛素样蛋白酶1除去重组蛋白的His标签。用纯化蛋白免疫大鼠,蛋白A/G混合琼脂糖纯化血清得到抗体。通过Western blot和免疫沉淀方法鉴定抗体的特异性。结果成功构建原核表达载体p ET-28m-ZMYND10,并获得可溶性表达。利用His柱得到高纯度的重组ZMYND10抗原,免疫大鼠后纯化得到的ZMYND10多克隆抗体可以检测到B16F10细胞中过表达及内源性表达的ZMYND10蛋白,并可用于免疫沉淀实验。结论本实验成功制备了ZMYND10的多克隆抗体,为后续探索ZMYND10在肿瘤细胞中的功能奠定了基础。 Objective To express and purify recombinant protein of Zinc finger MYND domain-containing protein 10( ZMYND10),and to make preparation of polyclonal antibody against mouse ZMYND10. Methods The open reading frame of mouse ZMYND10 gene was synthesized and subcloned into the prokaryotic expression vector p ET-28 m and transformed into E. coli BL21( DE3). His-ZMYND10 recombination protein was purified by His60 Ni gravity columns,and the His tab was removed by ubiquitin protease 1. The fusion protein His-ZMYND10 was used as antigen to immunize rats. The rat antiserum was purified by protein A / G mix agarose and its specificity was examined by Western blot and immunoprecipitation. Results Prokaryotic expression vector p ET-28m-ZMYND10 was built successful and was made solubility expression. The high purified restructuring ZMYND10 antigen was obtained by His60 Ni gravity columns and was used to immunize rats to produce polyclonal antibody against ZMYND10 which was used to detected the over-expression and endogenous expression of ZMYND10 protein in B16F10 cell used in immunoprecipitation. Conclusion Polyclonal antibody against ZMYND10 was successfully prepared,providing a firm foundation for future investigation on the function of ZMYND10 in tumor cells.
出处 《新乡医学院学报》 CAS 2015年第9期821-825,共5页 Journal of Xinxiang Medical University
基金 河南省高等学校重点科研项目(编号:15A180010)
关键词 锌指蛋白10 多克隆抗体 纯化 Zinc finger MYND domain-containing protein 10 polyclonal antibody purification
  • 相关文献

参考文献8

  • 1Hesson L B,Cooper W N,Latif F,et al.Evaluation of the 3p21.3tumour-suppressor gene cluster[J].Oncogene,2007,26(52):7283-7301.
  • 2Abe M,Ohira M,Kaneda A Y,et al.Cp G island methylatorphenotype is a strong determinant of poor prognosis in neuroblastomas[J].Cancer Res,2005,65(3):828-834.
  • 3Qiu G H,Tan L K,Loh K S,et al.The candidate tumor suppressor gene BLU,located at the commonly deleted region 3p21.3,is an E2F-regulated,stress-responsive gene and inactivated by both epigenetic and genetic mechanisms in nasopharyngeal carcinoma[J].Oncogene,2004,23(27):4793-4806.
  • 4Cheng Y,Ho R L,Chan K C,et al.Anti-angiogenic pathway associations of the 3p21.3 mapped BLU gene in nasopharyngeal carcinoma[J].Oncogene,2015,34:10.
  • 5Zhang X,Liu H,Li B,et al.Tumor suppressor BLU inhibits proliferation of nasopharyngeal carcinoma cells by regulation of cell cycle,c-Jun N-terminal kinase and the cyclin D1 promoter[J].BMC Cancer,2012,12:267-274.
  • 6Park S T,Byun H J,Kim B R,et al.Tumor suppressor BLU promotes paclitaxel antitumor activity by inducing apoptosis through the down-regulation of Bcl-2 expression in tumorigenesis[J].Biochem Biophys Res Commun,2013,435(1):153-159.
  • 7Dong S M,Byun H J,Kim B R,et al.Tumor suppressor BLU enhances pro-apoptotic activity of s MEK1 through physical interaction[J].Cell Signal,2012,24(6):1208-1214.
  • 8Zariwala M A,Gee H Y,Kurkowiak M,et al.ZMYND10 is mutated in primary ciliary dyskinesia and interacts with LRRC6[J].Am J Hum Genet,2013,93(2):336-345.

同被引文献11

  • 1KINAMERI E,INOUE T,ARUGA J,et al.Prdm proto-oncogene transcription factor family expression and interaction with the Notch-Hes pathway in mouse neurogenesis[J].PLo S One,2008,3(12):e3859.
  • 2GALLI G G,HONNENS DE LICHTENBERG K,CARRARA M,et al.PRDM5 regulates collagen gene transcription by association with RNA polymeraseⅡin developing bone[J].PLo S Genet,2012,8(5):e1002711.
  • 3SHU X S,GENG H,LI L,et al.The epigenetic modifier PRDM5functions as a tumor suppressor through modulating WNT/β-catenin signaling and is frequently silenced in multiple tumors[J].PLo S One,2011,6(11):e27346.
  • 4WATANABE Y,TOYOTA M,KONDO Y,et al.PRDM5 identified as a target of epigenetic silencing in colorectal and gastric cancer[J].Clin Cancer Res,2007,13(16):4786-4794.
  • 5NISHIKAWA N,TOYOTA M,SUZUKI H,et al.Gene amplification and overexpression of PRDM14 in breast cancers[J].Cancer Res,2007,67(20):9649-9657.
  • 6SHIVAPURKAR N,MAITRA A,MILCHGRUB S,et al.Deletions of chromosome 4 occur early during the pathogenesis of colorectal carcinoma[J].Hum Pathol,2001,32(2):169-177.
  • 7DENG Q,HUANG S.PRDM5 is silenced in human cancers and has growth suppressive activities[J].Oncogene,2004,23(28):4903-4910.
  • 8BOND C E,BETTINGTON M L,PEARSON S A,et al.Methylation and expression of the tumour suppressor,PRDM5,in colorectal cancer and polyp subgroups[J].BMC Cancer,2015,15:20.
  • 9GALLI G G,MULTHAUPT H A,CARRARA M,et al.PRDM5suppresses Apc-driven intestinal adenomas and regulates monoacylglycerol lipase expression[J].Oncogene,2014,33(25):3342-3350.
  • 10YANG H J,XIA Y Y,WANG L,et al.A novel role for neural cell adhesion molecule in modulating insulin signaling and adipocyte differentiation of mouse mesenchymal stem cells[J].J Cell Sci,2011,124(Pt 15):2552-2560.

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部